摘要
目的检测CXC趋化因子受体3(CXCR3)在甲状腺乳头状癌中的表达,分析其与甲状腺乳头状癌患者的相关临床参数之间的关系。方法采用免疫组织化学法分别检测48例甲状腺乳头状癌组织、42例甲状腺腺瘤以及13例正常甲状腺组织中CXCR3的表达情况。结果甲状腺乳头状癌组织中的CXCR3表达率显著高于甲状腺腺瘤组织和正常甲状腺组织(P值均<0.05);CXCR3表达水平的强弱差异与患者的年龄、性别和肿瘤的大小无相关性(P值均>0.05)。甲状腺乳头状癌组织中CXCR3表达为强阴性的淋巴结转移率为52.4%(11/21),显著高于CXCR3表达为阳性的28.6%(6/21,P<0.05)。结论 CXCR3在甲状腺乳头状癌组织中高表达,提示其可能是参与甲状腺乳头状癌淋巴转移的重要分子;CXCR3阳性表达的甲状腺乳头状癌具有较高的侵袭转移潜能,CXCR3可作为抑制甲状腺乳头状癌侵袭转移的有效靶点。
Objective To investigate the expression of CXC-chemokine receptor 3 （CXCR3） and its association with clinical features in papillary thyroid cancer. Methods Immunohistochemistry was used to detect the expression of CXCR3 in 48 papillary thyroid cancer, 42 thyroid adenomas and 13 normal thyroid tissues. Results The positive rate of CXCR3 in papillary thyroid cancer tissues was significantly higher than that in thyroidadenomas and normal thyroid tissues （both P〈0. 05）. The expression of CXCR3 was not significantly correlated with age, gender or the size of the tumor （all P〉 0. 05）, and was correlated with the degree of lymphatic metastasis （P〈0.05）. Conclusion CXCR3 is up-regulated in papillary thyroid cancer and associated with the progression of papillary thyroid cancer. CXCR3 may be a novel molecular marker to predict lymphatic metastasis and a new target to restrain metastasis. （Shanghai Med J, 2012, 35： 41-43）
出处
《上海医学》
CAS
CSCD
北大核心
2012年第1期41-43,共3页
Shanghai Medical Journal
基金
浦东新区重点学科群建设基金(PWZxkq2010-02)
上海市浦东新区青年基金项目(PW2010B-3)资助
